This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masri, S. Articles by Chen, S. Search for Related Content PubMed PubMed Citation Articles by Masri, S. Articles by Chen, S.

Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen Receptor

¹ Department of Surgical Research, ² Division of Information Sciences, and ³ Department of General Oncologic Surgery, Beckman Research Institute of the City of Hope, Duarte, California

Requests for reprints: Shiuan Chen, Department of Surgical Research, Beckman Research Institute of the City of Hope, 1500 E Duarte Road, Duarte, CA 91010. Phone: 626-359-8111, ext. 63454; Fax: 626-301-8972; E-mail: schen{at}coh.org.

Key Words: endocrine resistance • aromatase inhibitors • estrogen receptor • microarray

Acquired resistance to either tamoxifen or aromatase inhibitors (AI) develops after prolonged treatment in a majority of hormone-responsive breast cancers. In an attempt to further elucidate mechanisms of acquired resistance to AIs, MCF-7aro cells resistant to letrozole (T+LET R), anastrozole (T+ANA R), and exemestane (T+EXE R), as well as long-term estrogen deprived (LTEDaro) and tamoxifen-resistant (T+TAM R) lines were generated. This is the first complete panel of endocrine therapy–resistant cell lines, which were generated as multiple independent biological replicates for unbiased genome-wide analysis using affymetrix microarrays. Although similarities are apparent, microarray results clearly show gene signatures unique to AI-resistance were inherently different from LTEDaro and T+TAM R gene expression profiles. Based on hierarchical clustering, unique estrogen-responsive gene signatures vary depending on cell line, with some genes up-regulated in all lines versus other genes up-regulated only in the AI-resistant lines. Characterization of these resistant lines showed that LTEDaro, T+LET R, and T+ANA R cells contained a constitutively active estrogen receptor (ER) that does not require estrogen for activation. This ligand-independent activation of ER was not observed in the parental cells, as well as T+EXE R and T+TAM R cells. Further characterization of these resistant lines was performed using cell cycle analysis, immunofluorescence experiments to visualize ER subcellular localization, as well as cross-resistance studies to determine second-line inhibitor response. Using this well-defined model system, our studies provide important information regarding differences in resistance mechanisms to AIs, TAM, and LTEDaro, which are critical in overcoming resistance when treating hormone-responsive breast cancers. [Cancer Res 2008;68(12):4910–8]

This article has been cited by other articles:

				K. McCune, P. Bhat-Nakshatri, M. A. Thorat, K. P. Nephew, S. Badve, and H. Nakshatri Prognosis of Hormone-Dependent Breast Cancers: Implications of the Presence of Dysfunctional Transcriptional Networks Activated by Insulin via the Immune Transcription Factor T-bet Cancer Res., January 15, 2010; 70(2): 685 - 696. [Abstract] [Full Text] [PDF]

				C. Wong and S. Chen Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance Cancer Res., November 15, 2009; 69(22): 8670 - 8677. [Abstract] [Full Text] [PDF]

				I. Barone, Y. Cui, M. H. Herynk, A. Corona-Rodriguez, C. Giordano, J. Selever, A. Beyer, S. Ando, and S. A.W. Fuqua Expression of the K303R Estrogen Receptor-{alpha} Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway Cancer Res., June 1, 2009; 69(11): 4724 - 4732. [Abstract] [Full Text] [PDF]